Consultant - Cervical cancer

Tags: English Spanish Environment
  • Added Date: Wednesday, 24 April 2024
  • Deadline Date: Wednesday, 08 May 2024
5 Steps to get a job in the United Nations

..

Qualifications

Purpose of consultancy

To contribute to the development of technical products that can accelerate the pathway towards global elimination of cervical cancer.ย 

Background ย 

Cervical cancer affects over half a million women each year and causes over a quarter million deaths. Cervical cancer affects many of the most vulnerable in the world and strikes women in the prime of their life; nearly nine in ten women that die from cervical cancer live in low-income countries. ย Yet, cervical cancer is one of the most preventable and treatable forms of cancer, as long as it is detected early and managed effectively. ย Primary and secondary preventions are highly effective, with cost-effectiveness of โ‰ค USD 100 per day averted in low and middle-income countries.ย 

In 2018, the WHO Director General, made a call into action to eliminate cervical cancer as a public health problem. This call was followed by a WHO strategy to reach elimination with goals for 2030 on three pillars: reaching 90% of girls vaccinated against HPV infection by age 15, screening 70% of with a high-performance test at least twice in life and treating 90% of identified cervical disease and ensuring 90% of women with cervical cancer are given treatment and adequate care.

The 2021 WHO guidelines on screening and treatment to prevent cervical cancer recommend the use of HPV testing in primary screening, either on vaginal self-collected or cervical provider collected samples. Simple screening algorithms, screen-and-treat or screen, triage and treat are recommended to facilitate that most screened positives received treatment. HPV partial genotyping (i.e., using HPV16 and HPV18 individual results), visual inspection after acetic acid (VIA), cytology and colposcopy are among recommended triage tests, however, technology evolves fast and novel technologies can also be considered to increase efficiency of programmes and ensured best use of resources in low-and-middle income countries (LMIC). Countries need support and technical guidance to progress towards the 2030 goals.

The focus of this work includes a range of activities to contribute to the implementation and scale up of HPV based screening and treatment, including guidance for the development of WHO technical products such as 1) the living guidelines for cervical cancer screening and treatment, at which rapid aggregated evidence from novel technologies can be evaluated, 2) Target Product Profiles for HPV tests and other technologies, 3) guidance for HPV testing implementation in countries, 4) policy briefs on implementation research for cervical cancer prevention and control and, 5) other technical products. The activities may include working with countries and partners to better understand implementation successes and challenges.

In the context of the private sector dialogues, and to further support countriesโ€™ efforts to access High-performance HPV tests, WHO will organize activities with the private sector, inviting them to strengthen their commitment and contribution to increase access to HPV tests and facilitate implementation and scale-up of HPV-based cervical cancer screening. In coordination with WHO secretariat, the focus of this work includes a range of activities to support dialogues with the private sector, including the organization of meetings with procurers and manufacturers and preparing related meetings reports. The work may include interacting with country stakeholders and partners to better understand the needs for successful HPV testing scale up.

Deliverables

  • Output 1: Provide technical input in the development of living systematic reviews and recommendations on cervical screening and treatment of precancer lesions to prevent cervical cancer.
    • Deliverable 1.1: Organize WHO secretariat weekly meetings and online meetings (every two to three weeks) with sub-working group, to evaluate the evidence of technologies prioritised by the GDG. Provide technical input to the completion of systematic reviews and data analysis for the evaluation of evidence of GDG research priorities.
    • Deliverable 1.2: Organize full-working group meetings in June 2024 (virtual) and September 2024 (in-person); including preparation of background and thematic documents, agendas, summary notes and action points from each meeting; and completion of meeting reports after incorporating feedback from participants and WHO Secretariat.
    • Deliverable 1.3: Contribute to the publication of new/updated recommendations on cervical screening and treatment of precancer lesions to prevent cervical cancer.
    • Deliverable 1.4: Contribute to the completion of implementation guidance, including data consolidation from interviews and results presentations.
      Expected by: 30 April 2025
    • Output 2: Contribute to cervical cancer market shaping activities.

Recommended for you